Axsome Therapeutics has reached a settlement agreement with Hetero Labs to resolve a patent dispute related to Hetero Labs’s plans to release a generic of Sunosi, which is a sleep disorder therapy.

Axsome Therapeutics, Inc. has announced a settlement with Hetero Labs Ltd. regarding patent litigation over its product SUNOSI® (solriamfetol). The litigation arose from Hetero's application to market ...

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...

(RTTNews) - Axsome Therapeutics (AXSM) has entered into a settlement agreement with Hetero Labs Ltd. and certain of its affiliates resolving patent litigation related to Axsome's product SUNOSI. The ...

Takeda, Pfizer and other defendants sued Hetero Labs and its affiliated companies on March 19 in Delaware District Court alleging patent infringement. The suit, filed by Morris Nichols and WilmerHale, ...

Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; ...

Hetero Labs Limited Unit V and Hetero USA were hit with a patent infringement lawsuit on Jan. 9 in New Jersey District Court over their attempts to market a generic version of the prostate cancer drug ...

RAPS.org needs your explicit consent to store browser cookies. If you don't allow cookies, you may not be able to use certain features of the web site such as ...

Indian drugmakers Dr Reddy's, Hetero to sell generic HIV prevention drug for $40 a year Indian drugmakers Dr Reddy's Laboratories and Hetero Labs said on Wednesday that they will sell generic versions ...

Hetero Labs Ltd. has identified angiopoietin-1 receptor (TEK; hTIE2), EGFR (HER1; erbB1), hepatocyte growth factor receptor (HGFR; MET), proto-oncogene tyrosine-protein kinase receptor ret (RET; ...